However, in one family, a 5' 2.0 kb GPllla cDNA identified abnormal DNA fragments in the father and t w o affected siblings' genes. A series of restriction digests resulting in small genomic fragments were probed with portions of the 5' 2.0 kb GPllla cDNA and indicated that the abnormal sequences are flanked by normal fragments of the GPllla N 1918 GLANZMANN described a hereditary bleeding I disorder characterized by diminished clot retraction that he believed was due to an abnormality of blood platelets.' This disorder, which is inherited in a classical Mendelian autosomal recessive fashion, is now called Glanzmann's thrombasthenia. Platelets from these patients fail to aggregate when stimulated with a variety of physiologic agents. Nurden and Caen used electrophoretic analysis of the platelets from patients with this disorder to demonstrate the lack of plasma membrane glycoproteins IIb (GPIIb) and IIIa (GPIIIa).' The initial evidence implicating GPIIb and GPIIIa as the fibrinogen receptor came from studies of platelets from patients with Glanzmann's thrombasthenia in which fibrinogen binding was shown to be absent. ' There is now abundant evidence demonstrating that GPIIb-IIIa serves as the fibrinogen receptor on the surface of activated platelet^?^ Bleeding occurs in individuals with Glanzmann's thrombasthenia because their platelets are unable to bind fibrinogen, and hence, to aggregate and form a plug at the sites of vessel injury.
The GPJIb-IIIa complex is a member of the integrin family of cellular receptors involved in adhesive interactions."." These interactions participate in such diverse biologic processes as embryogenesis, inflammation, and metastases, as well as blood clotting (for review, see reference 12). These receptors have LY and @subunits that correspond to GPIIb and GPIIIa in platelets. GPIIIa is also present in human umbilical vein endothelial cells, where it is paired with a different a subunit to function as the vitronectin r e~e p t o r . '~. '~ The apparently unique expression of GPIIb by the megakary~cyte/platelet'~~" has led to the suggestion that defects in the GPIIb gene would be a more likely cause for Glanzmann's thrombasthenia, since defects in GPIIIa might be expected to affect nonhematopoetic tissues in which the vitronectin receptor is present.
Until recently, GPIIb-IIIa was undetectable by conventional techniques in most Glanzmann platelets." Sensitive immunoblot techniques have detected small amounts of GPIIb and/or GPIIIa in the platelets of most patients gene. To analyze further the genetic defect in this family, RNA was prepared from their platelets. Northern analysis revealed normal levels of GPllb mRNA compared t o control platelets. We were unable t o identify GPllla mRNA of any size in the clinically affected family members. We also identified an EcoRl restriction fragment length polymorphism (RFLP) that permitted carrier status determination in the clinically unaffected siblings. These studies indicate that Glanzmann's thrombasthenia can be caused by heterogeneous defects in the GPllla gene. Furthermore, we have shown that platelets can be used t o characterize normal and abnormal GPllla and GPllb mRNA, and RFLPs may be used t o determine the carrier status in some families with Glanzmann's thrombasthenia. The specific gene abnormality in this family appears t o represent an example of an insertional mutation resulting in a human disease. 0 1990 by The American society of Hematology.
studied." In rare instances, quantitatively normal but qualitatively abnormal GPIIb-IIIa complexes incapable of normal fibrinogen binding have been described.20-22 An interesting and unexplained observation is the reduction of both glycoproteins in the platelets of most affected individual^.^^ Why two different proteins are decreased in a single genetic disease is unknown, but previous studiesz4 have raised several possibilities. Physical linkage of the two genes to within 260 kilobases (kb) of one another on chromosome 17q21-2225 gave credence to a large deletion involving both genes as a possible mechanism of the thrombasthenic phenotype. Alternatively, a defect in the GPIIb or GPIIIa gene could result in the absence of one protein that is required for stability and membrane insertion of the other. Such a mechanism could be invoked to explain the normal amount of endothelial GPIIIa protein in one patient with Glanzmann's thrombasthenia.26 In this patient, it was speculated that the GPIIIa gene must, then, be intact, suggesting a defective GPIIb gene.
Since no genetic defect has been described yet in Glanzmann's thrombasthenia, we analyzed the genes for GPIIb and GPIIIa in a normal population and three kindreds with this disorder. Our studies indicate that Glanzmann's thrombasthenia can be caused by heterogeneous defects in the 882 BRAY AND SHUMAN GPIIIa gene and does not require a large gene deletion involving both genes.
MATERIALS AND METHODS
Blood from 30 normal volunteers was used to prepare DNA for Southern analysis (see below). Three kindreds (four affected individuals and their family members) with Glanzmann's thrombasthenia, cared for at the University of California at San Francisco Hemophilia Treatment Center, were analyzed. Diagnosis of affected individuals was based on all of the following criteria: ( I ) mucocutaneous bleeding since birth; (2) normal prothrombin and partial thromboplastin times; (3) normal platelet counts and morphology; (4) bleeding time greater than 30 minutes; (5) absent platelet aggregation in response to thrombin, adenosine diphosphate (ADP), epinephrine, collagen, and ionophore A23 187; (6) normal platelet aggregation in response to Ristocetin (Sigma Chemical Co, St Louis, MO); and (7) absent GPIIb and GPIIIa as assessed by Western immunoblotting (see below).
Western immunoblotting. Platelets were isolated by differential centrifugation;' and 10 pg of platelet membrane proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose.28 Immunoblots were performed using polyclonal antisera specific for GPIIb and/or GPIIIa as previously de~cribed.2~ Protein standards were obtained from Bio-Rad Laboratories, Richmond, CA.
DNA was extracted from peripheral blood lymphocytes according to standard techniq~es.'~ Genomic DNA ( 5 pg) was digested with restriction enzymes (New England Biolabs, Beverly, MA), electrophoresed in 0.8% agarose gels, transferred to nylon filters, and hybridized as de~cribed.'~ Hind111 digests of bacteriophage X were used as standards to estimate restriction fragment sizes.
Both GPIIb and GPIIIa cDNA clones were isolated from human erythroleukemia (HEL) cell cDNA The GPIIb cDNA is 3.3 kb and contains the entire coding region. GPIIIa probes used include a 2.0 kb GPIIIa fragment 5' to the internal EcoRI site of the cDNA and a 1.3 kb GPIIIa fragment 3' to the internal EcoRI site of the cDNA. The 1,000 bp and 775 bp GPIIIa probes were isolated after preparative digestion of the 5' 2.0 kb cDNA. The 481 bp probe contains additional cDNA sequence 5' to the 2.0 kb probe. A 264 bp GPIIIa probe overlapping 154 bp of the 3' end of the above 5' 2.0 kb probe was prepared by amplification of HEL cell GPIIIa cDNA using the polymerase chain reaction." Sense and antisense primers were synthesized from nucleotides 207 1 through 2094 and 231 1 through 2334, respectively, of the GPIIIa cDNA sequence." The 1.9 kb BamHI cDNA fragment for human 0 actin was purified from the pHF0A-1 pla~mid,~' and was a gift of Judy Chang, University of California, San Francisco. All probes were purified and isolated from either agarose or polyacrylamide gels.
Platelets were isolated as described;' and the platelet-rich plasma was carefully removed in order to minimize white blood cell (WBC) contamination. WBC contamination was approximately 1 per 3,000 platelets, as counted on a Technicon H-l (Technicon Instruments Corp, Tarrytown, NY). Total platelet RNA was prepared using the acid-guanidine phenol-chloroform method." RNA concentration was estimated by optical density (OD)260,280 readings of 10% (equivalent to 3 to 4 mL whole blood) of the total RNA preparation in 100 pL of water. This typically gave OD,, readings in the range of 0.1 to 0.2. Approximately 1.2 pg of total RNA was obtained per IO9 platelets. Based on these OD readings, 1.9 pg of total platelet RNA were electrophoresed through a formamide formaldehyde agarose gel in a "mini" gel apparatus, 6 cm x 8 cm (Aladin Enterprises, San Francisco, CA). Electrophoresis, transfer, and hybridizations were as previously described," using Subjects.
Southern analysis.
cDNA probes.
Northern analysis.
2 x lo6 cpm/mL hybridization solution. The actin probe required a 16-hour exposure to film, whereas the GPIIb and GPIIIa probes required 4 to 7 days.
RESULTS
Platelets of the affected individuals in three kindreds with Glanzmann's thrombasthenia were analyzed by Western blotting and lacked GPIIb and GPIIIa. (Affected members had all the clinical and laboratory characteristics of Glanzmann's thrombasthenia described in Materials and Methods.) Because two individuals in the kindred referred to as GT3 were subsequently found to have an abnormal GPIIIa gene, we did Western immunoblots using platelet membrane proteins from all members of this family (Fig 1) . Figure 1A shows this analysis using anti-GPIIIa antisera. Platelets from the normal control (lane l), both parents (lanes 2 and 3), and both unaffected children (lanes 6 and 7) contained GPIIIa. Neither affected child (lanes 4 and 5) had detectable GPIIIa by this technique. The high molecular weight protein (mol wt 190 Kd) is of uncertain significance, but may represent GPIIIa aggregates. The apparently equivalent amount of GPIIIa in the platelets of the parents (presumed obligate heterozygotes) compared with normal platelets is likely due to the semi-quantitative nature of Western immunoblotting (see Discussion). Similar Western analysis also revealed absence of GPIIb in the platelets of both affected children (Fig lB, lanes 1 and 2) . The antisera raised against GPIIb cross-reacts with both GPIIIa (lane 3) and a minor antigen migrating slightly faster than GPIIb (lanes 1 through 3). This latter antigen fortuitously confirms approximately equivalent amounts of platelet proteins in all lanes. Note that this evaluation does not allow carrier status determination of the unaffected siblings since heterozygotes have both GPIIb and GPIIIa protein. 34 Next, Southern analyses were performed using a t least three restriction enzymes on the DNA of four patients and an additional eight family members from three kindreds. Hybridization with a 3.3 kb full-length GPIIb cDNA yielded a normal banding pattern (data not shown). Thus, no gross abnormalities were detected in the GPIIb gene in any of the patients studied. Similar analysis of the GPIIIa gene revealed abnormalities in only kindred GT3. Figure 2 shows the initial Southern analyses of DNA from this family using GPIIIa cDNA probes. The 1.3 kb 3' GPIIIa probe only hybridized to a 4.1 kb TaqI fragment present in all family members and normal individuals (Fig 2, lanes 8 through 12) .
However, hybridization with the 5' probe for GPIIIa identi- that the two smaller 19.0 kb and 13.2 kb fragments seen in Fig 2A, lanes 2 through 4 are abnormal, do not represent polymorphisms and must derive from a mutant allele corresponding to the 5' GPIIIa cDNA probe. Clearly, these abnormal fragments come from the father's abnormal chromosome, and neither unaffected sibling has inherited the father's abnormal allele (lanes 5 and 6).
We used numerous restriction enzymes and probes to analyze further the mutant allele in this kindred. Preliminary experiments indicated that the most rewarding analysis was achieved using double restriction enzyme digests yielding fragments of genomic DNA from 2 to 15 kb. Therefore, we performed Southern analyses on a series of double digests of genomic DNA from a normal individual and the father in this kindred (Fig 3) . Two sets of digests are shown in each panel in Fig. 3 in order to exclude the possibility of coincidentally comigrating normal and abnormal fragments that might be observed in a single analysis. The most informative result in these studies is that the 5' 481 bp probe and the 3' 264 bp probe hybridized only to normal fragments of both alleles in the father's DNA (Fig 3, lanes 1 through 4   and 13 through 16) (Fig 3, lane 7 end of the 775 bp cDNA, which also indicated that this region of the father's gene was normal. Thus, the abnormal region of the father's mutant GPIIIa allele is contained within normal GPIIIa sequences. Because Glanzmann's thrombasthenia is an autosomal recessive disorder, the affected individuals in this kindred must also have inherited an abnormal GPIIIa gene from their mother. Since no large deletions or rearrangements of the mother's GPIIIa genes were detected, we analyzed further the genetic defect by determining the GPIIIa mRNA level in platelets from kindred GT3. Platelet RNA was prepared and subjected to Northern analysis using cDNA probes for GPIIIa, GPIIb, and human / 3 actin (Fig 4) . Figure  4A , lane 1 contains RNA from normal platelets and shows the appropriate 6.0 kb and 3.4 kb mRNAs for GPIIIa and GPIIb, respectively. As seen in lanes 4 and 5, platelets from both clinically affected family members contained GPIIb mRNA, but lacked GPIIIa mRNA. Based on the ethidium bromide stained gel, the stronger GPIIb signal in lane 5 was due to a larger amount of RNA loaded. The father's platelets contained mRNA for GPIIb and GPIIIa (lane 3). Because small amounts of RNA were analyzed and the exposure time required to detect signals was long, we were concerned about the sensitivity of such analysis. Therefore, we performed a second experiment in which platelet RNA from a normal control and a patient was probed with GPIIIa and human ( 3 actin cDNAs (Fig 4B) . Hybridization with the actin probe suggested that the filter contained more normal platelet RNA than patient platelet RNA (Fig 4B. lower panel) . However, the patient's platelets had markedly reduced levels of GPIIIa mRNA, compared with normal ( Fig 4B, upper  panel) . This decrease was much greater than could be accounted for by the difference in amount of RNA applied to the gel. Figure 4B also shows that within the limits of detection by this analysis, we were unable to identify an aberrant sized GPIIIa mRNA. Because our analysis had identified only one of the two mutant alleles in this kindred, another means was needed by which to track the mother's abnormal chromosome. Therefore, we looked for RFLPs in the GPIIb and GPIIIa genes. Genomic DNA from a minimum of 10 normal individuals was digested with various restriction enzymes (TuqI, EcoRI, BclI, XmuI, and BamHI) and analyzed by Southern blotting. Hybridizing with a full-length cDNA probe for GPIIb, we were unable to identify any RFLPs (data not shown). The TuqI RFLP for GPIIIa identified by ourselves and was uninformative in this family. Using the 3' GPIIIa probe we identified an EcoRI polymorphism (Fig 5) . When an allele containing this polymorphic site is digested with EcoRI, 17 kb and 2.0 kb fragments are observed. Lanes 3,5, and 6 show the heterozygous state; ie, one allele giving rise to the 19 kb fragment and the other allele, the 17 and 2.0 kb fragments. Lanes 2 and 4 represent the homozygous state processing the additional EcoRI site. Likewise, lane 1 shows the homozygous state lacking the additional site. 40 alleles were sampled, and 20 contained the additional EcoRI site, yielding an allelic frequency of approximately 50% for this polymorphism.
Lastly, we established the carrier status of the two unaffected siblings in kindred GT3. Figure 6 shows the Southern analysis of EcoRI-digested genomic DNA from all members of the family. Since Glanzmann's thrombasthenia is an autosomal recessive disorder, both alleles of the affected children (lanes 3 and 4) must be abnormal. The higher molecular weight 19 kb fragment must then, represent the abnormal allele inherited from the mother (lane 1) since the father is homozygous for the restriction site and doesn't have this band (lane 2). As shown in Fig 2, the two clinically unaffected children did not inherit the father's abnormal allele. The EcoRI RFLP reveals that the oldest of the two clinically unaffected children has inherited the mother's abnormal allele (Fig 6, lane 5 ) and, thus, is a carrier for the disease. The Youngest child has inherited neither abnormal allele (Fig 6, lane 6 ) . linkage of the genes for GPIIb and GPIIIa and the reduced levels of both proteins in most patients with this disease, it appears that defects in expression of just one of the two genes is sufficient to cause the thrombasthenic phenotype. Because GPIIIa is the B subunit of the platelet fibrinogen receptor, these studies provide further support for the importance of the GPIIb-IIIa complex in normal hemostasis.
Using Southern analyses, we examined a total of six GPIIb alleles and six GPIIIa alleles from affected individuals with Glanzmann's thrombasthenia and identified only a single abnormal allele. Lack of gross structural defects in the GPIIb and GPIIIa genes was also found by a group in Israel3' who studied 10 individuals with Glanzmann's thrombasthenia, suggesting that most defective alleles are due to either small mutations not readily defined by Southern analysis or mutations in the enhancer or promotor regions of the genes. Our data demonstrate an abnormal region of DNA present within the GPIIIa gene of the father and affected children in this family. Preliminary mapping studies indicate this abnormal region is at least 7.2 kb. Unequal crossover during meiosis or an insertion is a possible explanation for such findings. Although insertions of this size are common causes of mutations in Drosophila melanogaster and yeast, they are rare causes of human genetic diseases and raise the possibility of a retroviral transposable element.3' Both de novo and inherited mutations of this type have been des~ribed.~'.~ We are currently performing studies directed at cloning and sequencing the abnormal region of this mutation.
Using a monoclonal antibody specific for GPIIb, McEver et a1 found that platelets from parents of patients with Glanzmann's thrombasthenia contained 50% of the normal amount of GPIIb?4 We were able to detect GPIIIa in platelets from both parents in kindred GT3 using the technique of Western immunoblotting. In their original description of the method, Towbin et al were able to identify as little as 100 pg of protein.*' Since GPIIb and GPIIIa represent approximately 18% of the membrane glycoproteins in platelets and 10 pg of platelet membrane proteins were analyzed for each individual in Fig 1, it is not surprising that Western blotting is not sensitive to a 50% alteration in protein content. This emphasizes the semiquantitative nature of this technique.
Recently, Newman et al used the very sensitive polymerase chain reaction to demonstrate GPIIIa mRNA in normal platelets?' Our work shows the ability to detect GPIIIa and GPIIb mRNA by Northern analysis of total RNA from normal platelets. However, because only small quantities of RNA can be obtained from the amount of blood usually collected, small errors in the estimated concentration in each sample resulted in significant variation in the amount of RNA loaded on the gel. However, the ratio of GPIIIa to GPIIb or GPIIIa to actin allows one to compare the amount of GPIIIa mRNA in different samples. Exposure times of 4 to 7 days were required for the GPIIb and GPIIIa probed filters, again indicating this analysis is not as sensitive as when larger amounts of poly (A)+ RNA are used. The inability to detect GPIIIa RNA in the affected individuals in kindred GT3 could be due to unstable mRNA or defective transcription. However, because Glanzmann's thrombasthenia is an autosomal recessive disorder and the affected 1 2 3 4 5 6
Probe: 3' GPllla Fig 1 legend for symbol have demonstrated that heterogeneous mutations in the B subunit common to these three integrins causes LAD.42 Several lines of evidence indicate that the GPIIb genes in kindred GT3 are normal. First, Southern analyses of patient DNA using full-length GPIIb cDNA probes were normal. Second, Northern analysis of platelet GPIIb RNA indicates that it is of normal size and amount in these patients. Lastly, we have shown that the abnormality of the paternal DNA is confined to a region within the GPIIIa gene and does not include either the 5' or the 3' ends. Thus, since the gene for GPIIb is located 3' to the gene for GPIIIa,25 the paternal GPIIb gene cannot be part of the mutation. Taken together, this suggests that Glanzmann's thrombasthenia can occur despite an apparently intact GPIIb gene. The simplest interpretation would be that the GPIIb protein is unstable unless complexed with GPIIIa and is degraded before the appearance of the platelet in the peripheral circulation. LAD again serves as a model for such a mechanism since the a subunit of LFA-I, Mac-I, and p150,95 has been shown to require association with the B subunit in order to be transported to the cell ~u r f a c e .~' .~~ More recently, O'Toole et a1 have shown that both the GPIIb and GPIIIa subunits are needed for efficient surface expression of the complex in transfected monkey kidney cells.45 in the prediction of carrier status,47 and also in genetic linkage
We have identified an EcoRI RFLP that has allowed us to determine the carrier status of the unaffected members of this family. The relatively high frequency of these RFLPs in the general population may make them useful in other linkage analyses. Burke et were unable to identify an RFLP, presumably because their GPIIIa probe was 5' to the internal EcoRI site of the cDNA. Both the 1.3 kb and the 264 bp probes that were used to identify the EcoRI RFLP in these studies are located 3' to the internal EcoRI site of the cDNA. In fact, the 264 bp GPIIIa probe contains only 110 bp 3' to this site.
Finally, these results have interesting implications for the vitronectin receptor on endothelial cells. GPIIIa is also present in endothelial cells where it pairs with the CY subunit of the vitronectin receptor and binds vitronectin, fibronectin, and Because all evidence to date supports the existence of only one GPIIIa gene,25330 the affected individuals in the pedigree we have described must lack the endothelial form of GPIIIa. Since the clinical abnormalities in this family are confined to the hemostatic system, and they have normal wound healing, other platelet receptors may exist that bind ~itronectin,~" and/or other adhesive molecules could serve a substitute function for vitronectin.
RFLPs have been used clinically in prenatal
